case_images: PMC11184463_01
case_images: Brain images taken prior to immunotherapy. No abnormalities are obvious in fluid-attenuation inversion recovery (FLAIR) magnetic resonance imaging (A) or contrast-enhanced FLAIR imaging (B). Brain single-photon emission computed tomography displayed increased 99mTc-ECD uptake in the left frontotemporal region (C).
case_images: fimmu-15-1392992-g001.jpg
case_images: PMC11184463_01_fimmu-15-1392992-g001.jpg
case_images: f1
case_images: Brain magnetic resonance imaging (MRI) findings were normal; however, brain single-photon emission computed tomography revealed increased technetium-99m ethyl cysteinate dimer (99mTc-ECD) uptake in the left frontotemporal region ( Figure 1 ).
case_images: Timeline of clinical manifestations, treatment, and CSF and serum findings in our patient. ACV, acyclovir; FPHT, fosphenytoin; PB, phenobarbital; LEV, levetiracetam; LCM, lacosamide; IVMP, intravenous methylprednisolone; PSL, prednisolone; CSF, cerebrospinal fluid; WBC, white blood cell; NMDAR-ab, anti-N-methyl-D-aspartate receptor antibody; MOG-ab, anti-Myelin oligodendrocyte glycoprotein antibody; NA, not available; MMSE, Mini-Mental State Examination; FAB, Frontal Assessment Battery.
case_images: fimmu-15-1392992-g002.jpg
case_images: PMC11184463_01_fimmu-15-1392992-g002.jpg
case_images: f2
case_images: The timeline of the patient's clinical presentation, examination findings, and interventions is shown in  Figure 2 .
case_images: Study flowchart.
case_images: fimmu-15-1392992-g003.jpg
case_images: PMC11184463_01_fimmu-15-1392992-g003.jpg
case_images: f3
case_images: The flowchart of the study is shown in  Figure 3 .